Memphis Pharmaceuticals results, Q4 2025
Net profit, assets, equity and cash flow for Q4 2025, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit505 millionEGP · +163.9% vs the same period a year earlier
Total assets1.49 billionEGP · +22.7% vs the same period a year earlier
Shareholders' equity771 millionEGP · +416.9% vs the same period a year earlier
Operating cash flow86.89 millionEGP · −52.6% vs the same period a year earlier
In short
- Memphis Pharmaceuticals's net profit for Q4 2025 was about 505 million EGP, up +163.9% from 191 million EGP in Q4 2024.
- Total assets at the end of Q4 2025 were about 1.49 billion EGP, and shareholders' equity about 771 million EGP.
- Operating cash flow for Q4 2025 was positive at 86.89 million EGP.
Key lines against the same period a year earlier
This periodQ4 2024Change
Net profit505 million191 million+163.9%
Gross profit684 million309 million+121.4%
Total assets1.49 billion1.22 billion+22.7%
Total liabilities722 million1.07 billion−32.4%
Shareholders' equity771 million149 million+416.9%
Total liabilities and equity1.49 billion1.22 billion+22.7%
Operating cash flow86.89 million183 million−52.6%
Investing cash flow111 million30.59 million+263.1%
Financing cash flow-39.21 million163 million−124.1%
Net change in cash159 million376 million−57.8%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Memphis Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy